<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200691</url>
  </required_header>
  <id_info>
    <org_study_id>HangzhouCH09</org_study_id>
    <nct_id>NCT03200691</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>Phase II Study of Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hangzhou Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of radiation therapy
      combined with anti-PD-1 antibody SHR-1210 followed by surgery in treating patients with
      resectable esophageal squamous cell carcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>2-4 weeks after completion of radiotherapy</time_frame>
    <description>the Percentage of Patients Who Have No Evidence of Cancer in Their Surgical Specimen Following Surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.</measure>
    <time_frame>6 months</time_frame>
    <description>From the date of randomization to 6 months after esophagectomy. An expected average of 6 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Esophageal Diseases</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab with radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive neoadjuvant radiotherapy with concurrent anti-PD-1 antibody SHR-1210. Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40Gy/20f.
SHR-1210 200mg fixed dose every 2 weeks delivered concurrent with radiation therapy.
After 2-4 weeks of neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-DCRT or IMRT radiation</intervention_name>
    <description>Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f.</description>
    <arm_group_label>Nimotuzumab with radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-PD-1 antibody SHR-1210</intervention_name>
    <description>SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes.</description>
    <arm_group_label>Nimotuzumab with radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have histologically confirmed esophageal squamous cell carcinoma without
             prior treatments including surgery, chemotherapy, radiotherapy, and targeting
             treatment.

          2. With resectable disease of primary tumor in middle or lower thoracic esophagus and
             clinical stage Ⅱa-Ⅲ.

          3. age:18-75 years, male or female.

          4. Can provide either a newly obtained or archival tumor tissue sample.

          5. ECOG 0-1.

          6. Life expectancy of greater than 12 weeks.

          7. Without serious system dysfunction and could tolerate radiotherapy.

          8. Patients must have normal marrow function with a hemoglobin (HGB) of ≥90g/L, an white
             blood cell (WBC) counts of ≥4.0×109/L，a neutrophil count of ≥2.0×109/L, , a platelet
             count of ≥100×109/L, a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL), a
             creatinine (Cr) of ≤ 1.5 UNL, alanine aminotransferase (ALAT) and aspartate
             aminotransferase (ASAT) of ≤2.5 UNL.

          9. Patients must have normal electrocardiogram results and no history of congestive heart
             failure.

         10. Women of childbearing age should voluntarily take contraceptive measures.

         11. Without drug addition

         12. Patients must be with good compliance and agree to accept follow-up of disease
             progression and adverse events

         13. Patients must give written informed consent signed voluntarily by patients themselves
             or their supervisors witted by doctors.

        Exclusion Criteria:

          1. Patients who have or are currently undergoing additional chemotherapy, radiation
             therapy, targeted therapy or immunotherapy.

          2. With unresectable disease including any T4b or M1 disease

          3. Complete obstruction of the esophagus, or patients who have the potential to develop
             perforation

          4. Other malignancy within 5 years prior to entry into the study, expect for curatively
             treated basal cell and squamous cell carcinoma of the skin and/or curatively resected
             in-situ cervical and/or breast cancers.

          5. Known central nervous system (CNS) metastases.

          6. Subjects with any active autoimmune disease or history of autoimmune disease.

          7. Uncontrolled clinically significant heart disease, including but not limited to the
             following: (1) &gt; NYHA II congestive heart failure; (2) unstable angina, (3) myocardial
             infarction within the past 1 year; (4) clinically significant supraventricular
             arrhythmia or ventricular arrhythmia requirement for treatment or intervention;

          8. Active infection or an unexplained fever &gt; 38.5°C during screening or before the first
             scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion
             of the investigator);

          9. History of Interstitial Pneumonia or active non-infectious pneumonitis.

         10. Known Human Immunodeficiency Virus (HIV) infection、active Hepatitis B or Hepatitis C.

         11. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent.

         12. Known history of hypersensitivity to macromolecular protein preparation or any
             components of the SHR-1210 formulation.

         13. Concurrent medical condition requiring the use of cortisol (＞10mg/day Prednisone or
             equivalent dose) or other systematic immunosuppressive medications within 14 days
             before the study treatment. Except: inhalation or topical corticosteroids. Doses &gt; 10
             mg/day prednisone orequivalent for replacement therapy.

         14. Received a live vaccine within 4 weeks of the first dose of study medication.

         15. Pregnancy or breast feeding.

         16. Decision of unsuitableness by principal investigator or physician-in-charge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>shixiu wu, MD</last_name>
    <phone>+8657186826086</phone>
    <email>wushixiu@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hangzhou Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shixiu Wu, MD</last_name>
      <phone>+8657186826086</phone>
      <email>wushixiu@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hangzhou Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Shixiu Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Esophageal Squamous Cell Carcinoma</keyword>
  <keyword>PD-1</keyword>
  <keyword>Neoadjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

